Company news

Meiragtx Holdings Plc (NASDAQ:MGTX) news

Meiragtx Holdings Plc news releases on 6ix. Latest, Sep 23, 2026: MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board…

Meiragtx Holdings Plc (NASDAQ:MGTX) news

Press releases & updates

MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors

MeiraGTx Reports Second Quarter 2026 Financial and Operational Results

MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MEIRAGTX HOLDINGS PLC : COMPANY ANNOUNCEMENT : AMENDMENT NOTICE

MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares

MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia

MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026

MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results

ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy

MeiraGTx : Corporate Deck January

MeiraGTx Reports Third Quarter 2025 Financial and Operational Results

MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology

MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

MeiraGTx Reports Second Quarter 2025 Financial and Operational Results

MeiraGTx Reports First Quarter 2025 Financial and Operational Results

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease

MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates

MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson’s Disease and Industrialize MeiraGTx’s Proprietary Manufacturing Process

MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy

MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates

MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress

MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s Disease

MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference

MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi

MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results

MeiraGTx Reports First Quarter 2024 Financial and Operational Results

MeiraGTx to Participate in Upcoming Investor Conferences

MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference

MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates

MeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticals

MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million

MeiraGTx Announces Third Quarter 2023 Financial and Operational Results

MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities

MeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress

MeiraGTx Reports Second Quarter 2023 Financial and Operational Results

MeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-Oncology

MeiraGTx Announces its Wholly-Owned Gene Therapy Manufacturing Facility in Shannon, Ireland has Received Commercial MIA Authorization for QC Testing

MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company’s Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June ...

MeiraGTx Announces the Presentation of Nine Posters at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting

MeiraGTx Reports First Quarter 2023 Financial and Operational Results

MeiraGTx Announces $60 Million Private Placement of Ordinary Shares

MeiraGTx Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting

MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational Results

MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022